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Breast cancer resistance protein (BCRP/ABCG2) is
currently the only ABC transporter that exports mono-
and polyglutamates of folates and methotrexate (MTX).
Here we explored the relationship between cellular fo-
late status and BCRP expression. Toward this end,
MCF-7 breast cancer cells, with low BCRP and moderate
multidrug resistance protein 1 (MRP1/ABCC1) levels,
and their mitoxantrone (MR)-resistant MCF-7/MR sub-
line, with BCRP overexpression and low MRP1 levels,
were gradually deprived of folic acid from 2.3 M to 3 nM
resulting in the sublines MCF-7/LF and MCF-7/MR-LF.
These cell lines expressed only residual BCRP mRNA
and protein levels and retained a poor MRP2 (ABCC2)
through MRP5 (ABCC5) expression. Furthermore, MCF-
7/MR-LF cells also displayed 5-fold decreased MRP1 lev-
els relative to MCF-7/MR cells. In contrast, BCRP over-
expression was largely retained in MCF-7/MR cells
grown in MR-free medium containing 2.3 M folic acid.
Loss of BCRP expression in MCF-7/LF and MCF-7/
MR-LF cells resulted in the following: (a) a prominent
decrease in the efflux of Hoechst 33342, a BCRP sub-
strate; (b) an 2-fold increase in MR accumulation as
revealed by flow cytometry; this was accompanied by a
2.5- and 84-fold increased MR sensitivity in these cell
lines, respectively. Consistently, Ko143, a specific BCRP
inhibitor, rendered MCF-7 and MCF-7/MR cells 2.1- and
16.4-fold more sensitive to MR, respectively. Loss of
BCRP expression also resulted in the following: (c) an
identical MTX sensitivity in these cell lines thereby los-
ing the 28-fold MTX resistance of the MCF-7/MR cells;
(d) an 2-fold increase in the 4- and 24-h accumulation
of [3H]folic acid. Furthermore, MCF-7/MR-LF cells dis-
played a significant increase in folylpoly--glutamate
synthetase activity. Hence, consistent with the mono-
and polyglutamate folate exporter function of BCRP,
down-regulation of BCRP and increased folylpoly--glu-
tamate synthetase activity appear to be crucial compo-
nents of cellular adaptation to folate deficiency condi-
tions. This is the first evidence for the possible role of
BCRP in the maintenance of cellular folate homeostasis.
Reduced folate cofactors play a key role in one-carbon trans-
fer reactions in the de novo biosynthesis of purines and thymi-
dylate (1). As such, normal and neoplastic dividing cells have
an absolute requirement for reduced folates in order to properly
initiate and complete DNA replication and mitosis (1). Disrup-
tion of one-carbon transfer reactions in the folate metabolic
pathway by folic acid antagonists (i.e. antifolates) is the phar-
macological basis for the antitumor activity of methotrexate
(MTX)1 (2) as well as the novel antifolates raltitrexed (3) and
pemetrexed (4). Because mammalian cells are devoid of de novo
biosynthesis of folic acid, they must obtain this folate vitamin
from exogenous sources (1). Membrane transport of folates and
MTX is mediated by several systems (5, 6). (a) The reduced
folate carrier (RFC) is the major uptake route that functions as
a bi-directional anion exchanger (7, 8) taking up folates
through an antiport exchange mechanism with intracellular
organic phosphates (9). (b) Folate receptors mediate the unidi-
rectional uptake of folate cofactors into mammalian cells via an
endocytotic process (5, 10). (c) An apparently independent
transport system with optimal folate uptake activity at low pH
(11–13) is also known. Following uptake, the enzyme folylpoly-
-glutamate synthetase (FPGS) catalyzes the addition of sev-
eral equivalents of L-glutamic acid to the -carboxyl group in
the side chain of folate cofactors and antifolates like MTX (14).
This long chain polyglutamate conjugation (up to 10 glutamate
residues) is believed to fulfill three cellular functions as follows.
(a) By rendering folates and antifolates polyanionic, it dramat-
ically increases their cellular retention by preventing efflux
(15). (b) It increases the binding affinity of folate cofactors and
antifolates to some folate-dependent enzymes (4, 16). (c) It
appears to facilitate, via mitochondrial FPGS activity, the ac-
cumulation in mitochondria of folate polyglutamates that are
required for glycine biosynthesis (15).
Cellular folate pools are controlled by the above folate influx
systems, by FPGS activity, and by ATP-dependent efflux trans-
porters of the ABCC sub-family (17). Recent studies (18–22)
have established an increased energy-dependent folate and
MTX transport into inverted membrane vesicles isolated from
cell lines with MRP1 (ABCC1) through MRP4 (ABCC4) over-
expression. This MTX efflux in various tumor cell lines with
MRP overexpression resulted in a significant resistance to
MTX predominantly upon a short term (4 h) antifolate expo-
sure (18–20). The restriction of this antifolate resistance to
only a short term drug exposure has been attributed to the
ability of these transporters to export only monoglutamate but
not polyglutamate conjugates of MTX; indeed, these transport-
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ers failed to transport MTX diglutamates or longer chain poly-
glutamates (21, 22).
In contrast to the restricted ability of MRP1 through MRP4
to export only monoglutamate forms of folates and MTX, the
breast cancer resistance protein (BCRP/ABCG2) has been re-
cently found to transport both mono-, di-, and triglutamate
conjugates of folic acid and MTX in membrane vesicles isolated
from tumor cell lines with BCRP overexpression (23, 24). This
enhanced efflux of MTX in various tumor cell lines with the
wild type BCRP (Arg-482) resulted in a marked level of resist-
ance to this drug (25, 26). However, in contrast to the wild type
BCRP, two BCRP variants Thr-482 and Gly-482 completely
lost their ability to transport folates and MTX (23, 24, 27) and
therefore displayed a wild type sensitivity to MTX (24).
Apart from MTX, BCRP also extrudes various anticancer
drugs including MR, camptothecin-based and indocarbazole
topoisomerase I inhibitors, flavopiridol, and quinazoline ErbB1
inhibitors (28). Furthermore, efflux of anthracyclines is vari-
able and appears to depend on the presence of the above BCRP
mutation at position 482.
Here we initiated studies aimed at exploring the possible
involvement of BCRP in the maintenance of cellular folate
homeostasis. As a first step toward this end, MCF-7 and MCF-
7/MR cells with low and high BCRP levels, respectively, were
gradually deprived of folic acid. The resulting cell lines growing
under low folate (LF) conditions displayed a nearly complete
loss of BCRP mRNA and protein expression. Consequently,
these cell lines displayed a prominently diminished Hoechst
33342 efflux activity thereby resulting in markedly increased
sensitivity to both mitoxantrone (MR) and MTX. Consistent
with the ability of BCRP to export folate triglutamates, these
LF-adapted cell lines accumulated significantly more [3H]folic
acid than their parental counterparts. Furthermore, these cell
lines displayed a significantly increased FPGS activity. These
results constitute the first evidence that down-regulation of
BCRP expression along with increased FPGS activity are es-
sential components of cellular adaptation to folate deficiency
conditions. These findings suggest a functional role for BCRP
in the maintenance of folate homeostasis.
EXPERIMENTAL PROCEDURES
Chemicals—Folic acid, MTX, and 3,3-diaminobenzidine tetrahydro-
chloride were obtained from Sigma. Mitoxantrone hydrochloride was
from Cyanamid of Great Britain Ltd. (Gosport, Hampshire, UK). Ko143
was generously provided by Dr. A. H. Schinkel, The Netherlands Can-
cer Institute, Amsterdam, The Netherlands. Hoechst 33342 was pur-
chased from Molecular Probes (Eugene, OR). [3,5,7,9-3H]Folic acid
(69 Ci/mmol) was obtained from Moravek Biochemicals (Brea, CA) and
purified prior to use as described previously (29).
Tissue Culture and Folic Acid Deprivation—The human breast can-
cer cell line, MCF-7, and its MR-resistant MCF-7/MR subline (origi-
nally termed MCF-7/Mitox, see Ref. 30) with BCRP overexpression (31)
were grown as monolayers in RPMI 1640 medium containing 2.3 M
folic acid (Biological Industries, Beth-Haemek, Israel), 10% fetal calf
serum (Invitrogen) supplemented with 2 mM glutamine and 100 g/ml
penicillin and streptomycin. The growth medium of MCF-7/MR cells
also contained 0.1 M MR. In order to establish cell lines growing under
LF conditions, MCF-7 and MCF-7/MR cells were gradually deprived of
folic acid from 2.3 M (the standard concentration in RPMI 1640 me-
dium) to 3 nM resulting in the sublines MCF-7/LF and MCF-7/MR-LF;
this was achieved over a period of 3 and a half months in a folic acid-free
RPMI 1640 medium (Biological Industries, Beth-Haemek, Israel) sup-
plemented with 10% dialyzed fetal calf serum (Invitrogen) to which
gradually decreasing folic acid concentrations were added. In order to
examine the stability of BCRP expression during the omission of MR
from the growth medium, MCF-7/MR-HF cells were continuously cul-
tured in MR-free medium containing 2.3 M folic acid.
The human ovarian carcinoma cell line, 2008, and its sublines stably
transduced with MRP1, MRP2, and MRP3 cDNAs were kindly provided
by Prof. P. Borst (The Netherlands Cancer Institute, Amsterdam, The
Netherlands), whereas HEK293/MRP4 and HEK293/MRP5 cells were
used as positive controls for MRP4 and MRP5 overexpression, respec-
tively. These cell lines were cultured in RPMI 1640 medium containing
2.3 M folic acid, 10% fetal calf serum, 2 mM glutamine, and antibiotics.
Growth Inhibition with MR and MTX—For MR growth inhibition,
cells (1  104–1.75  104/well) were seeded in 24-well plates in growth
medium containing various concentrations of MR for 3–5 days at 37 °C.
For MTX growth inhibition, cells were allowed to attach for 24 h at
37 °C. Attached cells were then exposed to various concentrations of
MTX for 4 h at 37 °C, following which the drug-containing medium was
aspirated, and three successive 10-min washes in RPMI 1640 contain-
ing 10% dialyzed fetal bovine serum at 37 °C were performed. Drug-free
medium was added (2 ml/well), and cultures were incubated for 4 days
at 37 °C. After incubation with MR or MTX, cells were detached by
trypsinization, and the number of viable cells was determined by using
trypan blue exclusion.
Western Blot Analysis of MRPs and BCRP Expression—To examine
the expression of various MRPs and BCRP in the different cell lines,
non-ionic detergent-soluble proteins were extracted from2 107 cells
in a buffer (250 l) containing 50 mM Tris, pH 7.5, 50 mM -mercapto-
ethanol, 0.5% Triton X-100, and the protease inhibitors aprotinin (60
g/ml), leupeptin (5 g/ml), phenylmethylsulfonyl fluoride (10 g/ml),
and EGTA (1 mM). Following 1 h of incubation on ice, the extract was
centrifuged at 15,000  g for 30 min at 4 °C, and the supernatant
containing the fraction of Triton X-100-soluble proteins was collected,
and protein content was determined using the Bio-Rad protein assay.
Proteins (6–60 g) were resolved by electrophoresis on 7% (for MRPs)
or 10% (for BCRP) polyacrylamide gels containing SDS and electro-
blotted onto a Protran BA83-cellulose nitrate membrane (Schleicher &
Schuell). The blots were blocked for 1 h at room temperature in TBS
buffer (150 mM NaCl, 0.5% Tween 20, 10 mM Tris, pH 8.0) containing
1% skim milk. The blots were then reacted with the following anti-
human MRP monoclonal antibodies (kindly provided by Prof. R. J.
Scheper, Vrije Universiteit Medical Center, Amsterdam, The Nether-
lands): rat anti-MRP1 (MRP-r1; 1:1000), -MRP4 (M4I-10; 1:500), -MRP5
(M5I-1; 1:750), and -BCRP (BXP-53; 1:1000) as well as mouse anti-
MRP2 (M2III-5; 1:50) and -MRP3 (M3II-21; 1:500). Blots were then
rinsed in the same buffer for 10 min at room temperature and reacted
with horseradish peroxidase-conjugated goat anti-mouse or anti-rat
IgG (1:10,000 dilution, Jackson ImmunoResearch, West Grove, PA) for
1 h at room temperature. Following three 10-min washes in TBS at
room temperature, enhanced chemiluminescence detection was per-
formed according to the manufacturer’s instructions (Biological Indus-
tries, Beth-Haemek, Israel). To normalize for loading differences, the
nylon membranes were stripped and reacted with an antibody against
-tubulin (clone 2-28-33 from Sigma; 1:4000).
Immunohistochemistry Studies—Mid-logarithmic monolayers in 24-
well plates were washed twice with PBS and fixed with 4% formalde-
hyde for 10 min. Endogenous peroxidase activity was neutralized by
incubation for 20 min in a solution consisting of 4 volumes of methanol
and 1 volume of 3% H2O2 in double distilled water. The fixed cells were
washed twice with PBS, blocked for 1 h at room temperature in PBS
containing 1% skim milk, and reacted with an anti-BCRP monoclonal
antibody BXP-53 (1:100 dilution). Then a horseradish peroxidase-con-
jugated goat anti-rat IgG (1:100 dilution) was added. Color development
was performed with the chromogen 3,3-diaminobenzidine (0.6 mg/ml)
in a solution containing 50 mM Tris-Cl, pH 7.6, and 0.02% H2O2. After
counterstaining with hematoxylin, cells were examined with an Olym-
pus BH-2 upright light microscope.
On-line Efflux of Hoechst 33342—Efflux of Hoechst 33342 was meas-
ured by using an on-line computerized method. Cells were cultured on
glass coverslips that fitted to the wall of a 1  1  4-cm cuvette (width,
depth, and height, respectively). Cells were loaded with 10 M Hoechst
33342 for 2 h at 37 °C in a phenol red-free RPMI 1640 medium (Invitro-
gen) until steady state was achieved. Cells were then transferred to ice
until the efflux was initiated. To follow Hoechst 33342 efflux, the
coverslips were washed twice with ice-cold medium and then placed in
a cuvette that contained 3 ml of warm (37 °C) medium. The fluorescence
in the extracellular medium originating from the extruded chro-
mophore was monitored on-line with a spectrofluorometer (FluoroMax,
SPEX Industries, Edison, NJ). Hoechst 33342 fluorescence was meas-
ured every second at an ultraviolet excitation of 318 nm and emission at
460 nm. To correct for fluctuations in the number of cells/slide, cell
numbers were determined by adding 0.4 M of the DNA dye Syto 13
(Molecular Probes, Eugene, OR). The fluorescence of Syto 13 was de-
termined at excitation and emission wavelengths of 485 and 520 nm,
respectively. Hoechst 33342 fluorescence was then normalized for the
individual Syto 13 signals.
[3H]Folic Acid Accumulation—Adherent cells (1  106) in 6-cm
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Petri dishes (Nunc) were washed three times in folic acid-free RPMI
1640 containing 10% dialyzed fetal calf serum (Invitrogen). Following
an equilibration for 2 h in the same medium at 37 °C, [3H]folic acid (69
Ci/mmol, Moravek Biochemicals, Brea, CA) was added to a final con-
centration of 1 M (specific radioactivity 1,200 dpm/pmol) and incubated
at 37 °C for 4 and 24 h. Transport was stopped by the addition of 10 ml
of ice-cold HBS containing 20 mM Hepes, 140 mM NaCl, 5 mM KCl, 2 mM
MgCl2, and 5 mM D-glucose, pH 7.4, with NaOH (32). Cells were then
washed three times in ice-cold HBS, detached by trypsinization,
counted, and centrifuged at 500  g for 5 min at 4 °C, and the radio-
activity was determined using an Ultima Gold scintillation fluid and a
scintillation spectrometer (Packard Instrument Co.). Controls for accu-
mulation of radiolabeled folic acid contained a 1000-fold excess of un-
labeled folic acid (1 mM).
Flow Cytometric Analysis of MR Staining—Exponentially growing
MCF-7, MCF-7/MR, and their LF-adapted cell sublines were
trypsinized, adjusted to a density of 5  105–1  106/ml, and incubated
in growth medium containing 20 M MR for 1 h at 37 °C. Cells were
then harvested by centrifugation at 4 °C, washed once with ice-cold
PBS, and analyzed for mean fluorescence intensity per cell by a FAC-
SCalibur flow cytometer (BD Biosciences). Excitation was at 633 nm
and emission at 661 nm. Autofluorescence intensities of unstained cells
were recorded and subtracted from those of MR-stained cells.
FPGS Activity Assay—Frozen pellets of 2  107 cells grown in the
absence of drugs for 3–4 passages were suspended in 0.5 ml of an
extraction buffer containing 50 mM Tris-HCl, 20 mM KCl, 10 mM MgCl2,
and 5 mM dithiothreitol, pH 7.5. Total cell extracts were obtained by
sonication (MSE Soniprep, amplitude 14 m, three times for 5 s with
10-s intervals at 4 °C) followed by centrifugation at 12,000  g for 15
min at 4 °C. The FPGS activity assay mixture contained 200 g of
protein, 4 mM L-[2,3-3H]glutamic acid (specific activity 6.6 mCi/mmol)
and 250 M MTX in a buffer consisting of 100 mM Tris, pH 8.5, 10 mM
ATP, 20 mM MgCl2, 20 mM KCl, and 10 mM dithiothreitol in a final
volume of 250 l (33). Following 2 h of incubation at 37 °C, the reaction
was stopped by adding 1 ml of an ice-cold solution containing 5 mM
unlabeled L-glutamic acid. Sep-Pak C18 cartridges (Millipore, Waters
Associates, Etten-Leur, The Netherlands) were used for the separation
of free, unreacted L-[3H]glutamate from MTX-[3H]diglutamate. Con-
trols lacking MTX were included in order to correct for polyglutamyla-
tion of endogenous folates present in the cell extract.
Semi-quantitative RT-PCR and DNA Sequencing—Following RNA
isolation using the TriReagent protocol (Sigma) and cDNA synthesis, a
172-bp human BCRP fragment was PCR-amplified using the upstream
primer 5-TGCCCAAGGACTCAATGCAACA-3 and the downstream
primer 5-ACAATTTCAGGTAGGCAATTGTG-3 as described previ-
ously (34). The primers for glyceraldehyde-3-phosphate dehydrogenase,
and PCR conditions were as described recently (35).
To analyze whether BCRP in parental MCF-7 cells and their MCF-
7/MR subline harbored the wild type Arg-482, we performed DNA
sequencing of this region using an ABI Prism 310 DNA Sequencer
(AME Bioscience). To this end, BCRP primers were designed using the
LightCycler Probe Design Software version 1.0 (Idaho Technology Inc.);
the upstream and downstream primers are 5-CAGCGGATACTACA-
GAG-3 and 5-GCCGTAAATCCATATCGTG-3, respectively. All cell
lines were homozygous for the wild type Arg-482.
Statistical Analysis—We used a Student’s t test to examine the
significance of the difference between two populations for a certain
variable. A difference between the average of two populations was
considered significant if the p value obtained was 0.05.
RESULTS
Loss of BCRP Expression in the LF-adapted Cell Lines as
Revealed by Western Blot Analysis—The levels of BCRP as well
as MRP1 through MRP5 were determined in MCF-7/LF and
MCF-7/MR-LF cells relative to their parental counterparts
(Fig. 1). Western blot analysis revealed that folate deprivation
in MCF-7/LF cells resulted in an 18-fold decrease in BCRP
levels, relative to parental MCF-7 cells (Fig. 1A); in contrast, no
changes were observed in MRP1 levels (Fig. 1B). Similarly,
whereas MR-resistant MCF-7/MR cells displayed an 55-fold
BCRP overexpression, relative to parental MCF-7 cells, the
MCF-7/MR-LF subline expressed only residual BCRP levels
(Fig. 1A); remarkably, these barely detectable levels of BCRP
in MCF-7/MR-LF cells were 4-fold lower than those present
in MCF-7 cells. Furthermore, folate deprivation in MCF-7/
MR-LF cells resulted in a simultaneous 5-fold decrease in
MRP1 levels, relative to their parental MCF-7/MR cells (Fig.
1B). It should be noted that when compared with parental
MCF-7 cells, MCF-7/MR cells contained 3-fold less MRP1 levels
even before gradual folate deprivation was initiated. Most im-
portant, MCF-7/MR-HF cells grown in the absence of MR but in
the continuous presence of 2.3 M folic acid had only a slight
decrease in BCRP expression, relative to the near-complete loss
of BCRP in MCF-7/MR-LF cells (Fig. 1A).
Retention of Poor MRP2 through MRP5 Expression in the
LF-adapted Cell Lines—MRP2, MRP3, and MRP4 have the
facility to export folates, whereas previously, MRP5 was not
shown to export folates and MTX (summarized in Ref. 17);
therefore, we determined the levels of these transporters in the
LF-adapted cell lines (Fig. 1B). MRP2, MRP3, and MRP5 were
essentially undetectable in both parental cells and their LF-
adapted sublines, whereas MRP4 was expressed at equally low
levels in both cells lines (Fig. 1B). Reprobing with a -tubulin
monoclonal antibody was used to correct for any differences in
the amounts of Triton X-100-soluble proteins that were being
analyzed (Fig. 1, A and B).
Poor BCRP Gene Expression in the LF-adapted Cell Lines as
Revealed by RT-PCR—We next examined by semi-quantitative
RT-PCR analysis whether the marked loss of BCRP protein
levels in the LF-adapted cell lines was because of decreased
BCRP gene expression. Parental MCF-7 cells expressed nota-
ble levels of BCRP mRNA, whereas MCF-7/MR-HF cells dis-
played a prominent overexpression of BCRP mRNA (Fig. 1C).
In contrast, the LF-adapted sublines MCF-7/LF and MCF-7/
MR-LF contained only residual levels of BCRP mRNA (Fig. 1C,
upper panel). An RT-PCR of a housekeeping gene (glyceralde-
hyde-3-phosphate dehydrogenase) confirmed that comparable
FIG. 1. Western blot analysis of BCRP as well as MRP1 through
MRP5 expression in parental cells and their LF-adapted cell
lines. Aliquots of Triton X-100-soluble membrane proteins (6–60 g)
were separated by electrophoresis on 7.5% polyacrylamide gels contain-
ing SDS and electroblotted onto a Protran nylon membrane. Then the
membranes were reacted with monoclonal antibodies against BCRP (A)
or MRP1 through MRP5 (B), following which a second peroxidase-
conjugated antibody was added, and membranes were developed using
a standard ECL procedure. To correct for loading differences, the blots
were stripped and reprobed with an antibody against -tubulin. Note
that in order to estimate the barely detectable BCRP expression in the
LF-adapted cell lines (A), the MCF-7/LF and MCF-7/MR-LF lanes were
intentionally loaded with excess protein (60 g) relative to their paren-
tal counterparts (30 g). The control lane in B contained membrane
protein extracts (6 g) from cell lines with overexpression of MRP1
through MRP5 as described under “Experimental Procedures.” Semi-
quantitative RT-PCR analysis was performed in order to estimate
BCRP gene expression in the LF-adapted cell lines as compared with
their parental cells (C). A parallel RT-PCR with glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used in order to normalize for
the amounts of total cDNA used in each lane (see “Experimental Pro-
cedures”). Note that an3-fold lower level of MCF-7/MR-HF cDNA was
analyzed in order to retain comparability of signal intensity (C).
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levels of cDNA were being analyzed in the various cell lines
(Fig. 1C, lower panel).
Loss of BCRP Expression in the LF-adapted Cell Lines as
Revealed by Immunohistochemistry—To confirm the loss of
BCRP expression in the LF-adapted cell lines, we performed
immunohistochemistry with BXP-53, a novel monoclonal anti-
body to BCRP (Fig. 2). MCF-7/MR cells growing in the contin-
uous presence of 0.1 M MR displayed an intense cellular
staining (Fig. 2A) and a clear plasma membrane localization
(Fig. 2A, arrows). Consistently, MCF-7/MR-HF cells growing in
a medium lacking MR but containing 2.3 M folic acid retained
a relatively strong cellular staining (Fig. 2B). In contrast, the
poor BCRP expression in MCF-7/MR-LF cells (Fig. 2C), MCF-
7/LF cells (Fig. 2E), and the low BCRP levels in parental
MCF-7 cells (Fig. 2D) were below the level of detection by
immunohistochemistry.
Loss of Hoechst 33342 Efflux in the LF-adapted Cell Lines—
In order to determine whether the marked loss of BCRP ex-
pression in the LF-adapted cell lines was associated with a
parallel fall in BCRP export activity, we used an on-line efflux
assay (36) of Hoechst 33342. In this functional assay, mono-
layer cells were loaded with 10 M of the chromophore Hoechst
33342, an established BCRP efflux substrate (37). After 2 h of
loading at 37 °C, the culture medium was replaced by a fluoro-
phore-free medium, and the extent of Hoechst 33342 efflux was
continuously monitored by measuring the increase in the fluo-
rescence in the external medium (Fig. 3). MCF-7/MR-HF cells
with BCRP overexpression displayed a marked efflux of Ho-
echst 33342, whereas parental MCF-7 cells with low BCRP
expression had a lower efflux. In contrast, the LF-adapted
sublines MCF-7/LF and MCF-7/MR-LF cells, which essentially
lost BCRP expression, had only a background efflux of Hoechst
33342; curve fitting of these efflux data confirmed the poor
efflux of Hoechst 33342 in the LF-adapted cell lines (Fig. 3,
inset). Thus, loss of BCRP expression was accompanied by a
parallel fall in the efflux of Hoechst 33342, an established
BCRP substrate.
Accumulation of MR in the LF-adapted Cell Lines as Re-
vealed by Flow Cytometry—We further explored by flow cytom-
etry whether the loss of BCRP expression and efflux function
would consistently result in increased MR accumulation in the
LF-adapted cell lines (Fig. 4). Indeed, upon a 1-h incubation
with 20 M MR, MCF-7/MR-LF and MCF-7/LF cells displayed
statistically significant (p  0.003 and p  0.018, respectively)
increases of 1.9- and 2.0-fold in the net accumulation of MR,
respectively, relative to their parental cells (Fig. 4).
Sensitivity of the LF-adapted Cell Lines to MR—We therefore
examined whether the loss of BCRP expression and MR efflux
activity was also accompanied by an increase in MR sensitivity
in the LF-adapted cell lines. MCF-7/LF cells that essentially
lost BCRP expression exhibited a 2.5-fold increased sensitivity
to MR, relative to parental MCF-7 cells (Fig. 5A). Consistently,
MCF-7/MR-HF cells displayed a 34-fold resistance to MR, rel-
ative to parental MCF-7 cells (Fig. 5B), whereas MCF-7/MR-LF
cells that lost BCRP expression and efflux activity exhibited
84-fold increased sensitivity to MR, relative to their MCF-7/
MR-HF counterpart (Fig. 5B). Most important, disruption of
BCRP efflux activity in MCF-7 and MCF-7/MR-HF cells by the
specific and potent BCRP inhibitor Ko143 (38) rendered these
cell lines 2.1- and16.4-fold more sensitive to MR, respectively
(Fig. 5, A and B, respectively).
Loss of MTX Resistance in MCF/MR-LF Cells—BCRP was
shown to export MTX, thereby conferring resistance to this
antifolate, particularly upon short term drug exposure (25, 26).
When compared with parental MCF-7 cells, MCF-7/MR cells
displayed only 2-fold resistance upon a continuous MTX expo-
sure (Fig. 6A) but as high as 28-fold resistance to MTX upon 4 h
of antifolate exposure (Fig. 6B). In contrast, loss of BCRP
expression in MCF-7/MR-LF cells resulted in a complete loss of
MTX resistance upon 4 h of drug exposure, thereby resulting in
an IC50 value (80 nM) that was identical to that obtained with
MCF-7/LF cells (Fig. 6C).
Increased Accumulation of [3H]Folic Acid in the LF-adapted
Cell Lines—We next examined the ability of the LF-adapted
cell lines to accumulate [3H]folic acid as compared with their
parental cell lines. After 4 (Fig. 7A) and 24 h of incubation (Fig.
7B) with 1 M [3H]folic acid at 37 °C, MCF-7/LF and MCF-7/
MR-LF cells displayed an 2-fold increase in the accumulation
of [3H]folic acid relative to their parental counterparts. This
increased accumulation of [3H]folic acid after 4 and 24 h of
incubation was statistically significant for both MCF-7/LF (p 
0.015 and 0.026, respectively) and MCF-7/MR-LF cells (p 
0.031 and 0.033, respectively), when compared with their pa-
rental cells. In contrast, the trivial elevation in the accumula-
tion of [3H]folic acid after 4 and 24 h in MCF-7/MR-HF cells
relative to MCF-7/MR cells was not statistically significant
(p  0.549 and 0.249, respectively).
Increased Folylpoly--glutamate Synthetase Activity in the
LF-adapted Cell Lines—In a previous study we have shown
that gradual folate deprivation achieved by a stepwise increase
in the antifolate pressure resulted in a substantial increase in
FPGS activity (39) in pyrimethamine-resistant Chinese ham-
FIG. 2. Immunohistochemical detection of BCRP expression in parental cells and their LF-adapted cell lines. Exponentially growing
MCF-7/MR (A), MCF-7/MR-HF (B), MCF-7/MR-LF (C), MCF-7 (D), and MCF-7/LF (E) cells in 24-well culture plates were fixed with 4%
formaldehyde and reacted with the anti-BCRP monoclonal antibody BXP-53. Then a horseradish peroxidase-conjugated rabbit anti-mouse IgG was
added, and color development was carried out using the chromogen 3,3-diaminobenzidine. Finally, cells were counterstained with hematoxylin and
examined with a light microscope at a 200 magnification. The arrows in A denote the plasma membrane localization of BCRP in MCF-7/MR cells
growing in the continuous presence of 0.1 M MR. Note that MCF-7/MR-HF cells (B) were grown for 3 and a half months in MR-free medium
containing 2.3 M folic acid.
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ster ovary cells (40). Here, consistently, folate deprivation re-
sulted in statistically significant increases of 63 (p 0.001) and
20% (p  0.008) in FPGS activity in MCF-7/MR-LF and MCF-
7/LF cells, respectively, relative to their parental counterparts
(Fig. 8). In summary, the gradual folate deprivation in MCF-7
and MCF-7/MR cells resulted in the loss of BCRP expression
and efflux function as well as in a significant increase in the
activity of FPGS, the key enzyme responsible for cellular re-
tention of long chain (3 glutamate residues) folate
polyglutamates.
DISCUSSION
Whereas MRP1 through MRP4 export folate and MTX mono-
glutamates, only BCRP has the facility to extrude both mono-,
di-, and triglutamate conjugates of folic acid and MTX (23, 24).
We hence undertook the present study in order to explore the
possible role of BCRP in folate homeostasis in cells with a
ubiquitous expression of MRP1. To this end, we first examined
the relationship between folate status and BCRP expression.
We therefore performed a gradual folic acid deprivation by
using two sets of breast cancer cell lines as follows: parental
MCF-7 cells with low BCRP expression and moderate MRP1
levels, as well as their MR-resistant MCF-7/MR subline with
high levels of BCRP but low levels of MRP1. Several lines of
evidence established that folate deprivation resulted in a dra-
matic down-regulation of BCRP expression and efflux function.
(a) Semi-quantitative RT-PCR and Western blot analyses re-
vealed only residual BCRP gene expression and protein levels,
respectively, in both LF-adapted cell lines. (b) Immunohisto-
chemistry studies demonstrated that MCF-7/MR cells had an
intense plasma membrane staining and a marked intracellular
staining, whereas their LF-adapted subline MCF-7/MR-LF was
devoid of plasma membrane and cytoplasmic staining. (c) Al-
though MCF-7/MR-HF and MCF-7 cells displayed a high and
low efflux of the BCRP substrate Hoechst 33342, respectively,
only residual chromophore efflux was obtained with the LF-
adapted sublines. (d) Consistently, the LF-adapted cell lines
exhibited a significant increase in the net accumulation of MR,
relative to their parental cells. (e) Folate deprivation resulted
in the loss of resistance to the established BCRP substrates MR
and MTX in MCF-7/MR-LF cells as well as in a markedly
increased sensitivity of MCF-7/LF cells to these drugs. Fur-
thermore, the extent of the increased sensitivity to MR in the
LF-adapted cell lines was comparable with that achieved with
MCF-7 and MCF-7/MR cells that were treated with Ko143, a
potent and specific BCRP inhibitor (38). Based on these cumu-
FIG. 3. On-line efflux of Hoechst 33342 from monolayers of parental and LF-adapted cell lines. Following loading of MCF-7/MR-HF
(dark blue tracing), MCF-7/MR-LF (yellow), MCF-7 (purple), and MCF-7/LF cells (light blue/green) with 10 M Hoechst 33342, cells were washed,
and the fluorescence of the extruded chromophore in the extracellular medium was continuously monitored (every second for up to 5000 s) by an
on-line computerized spectrofluorometer. The fluorescence depicted was obtained after normalization for differences in the number of cells per well;
this was achieved by DNA staining with Syto 13 as described under “Experimental Procedures.” Inset, curve-fitting of the Hoechst 33342 efflux
data was performed as described previously by Wielinga et al. (46).
FIG. 4. Flow cytometric analysis of MR accumulation in paren-
tal cells and their LF-adapted cell lines. Exponentially growing
cells were detached by trypsinization and incubated in growth medium
containing 20 M MR for 1 h at 37 °C. Cells were then washed with
ice-cold PBS and analyzed for mean linear fluorescence per cell using a
flow cytometer. Cellular MR fluorescence was obtained after subtrac-
tion of the autofluorescence of unstained cells. Results presented are
means S.D. of three independent experiments performed in duplicate.
The asterisks denote statistically significant (Student’s t test) changes
in MCF-7/LF versus its parental MCF-7 cells, as well as MCF-7/MR-LF
versus its MCF-7/MR-HF parental counterpart.
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lative data, we conclude that down-regulation of BCRP expres-
sion and efflux activity is an essential component of cellular
survival under conditions of folate deficiency. These results
support the hypothesis that apart from MRP1, BCRP is an
important component of folate homeostasis, particularly under
conditions of folate deprivation.
We note that loss of BCRP expression and function in MCF-
7/MR-LF cells was not the sole adaptive response to folate
deprivation. When compared with parental MCF-7 cells, MCF-
7/MR-LF cells showed a 14-fold decrease in MRP1 levels. More-
over, the latter cells also displayed a 63% increase in FPGS
activity relative to their parental MCF-7/MR-HF counterpart.
Thus, MCF-7 cells growing in an excess of folic acid in the
growth medium (i.e. 2.3 M) initially had a substantial capacity
to actively export folates via MRP1 and BCRP but only poorly
via MRP4. In contrast, MCF-7/MR-LF cells growing in an
770-fold less folic acid in the growth medium essentially lost
this ability to export folates via MRP1 and BCRP. It should be
emphasized that whereas MRP2, MRP3, and MRP4 have the
facility to extrude folates, these transporters were essentially
undetectable or poorly expressed in both parental cells and the
LF-adapted cell lines. The increased activity of FPGS along
with the loss of BCRP and the markedly decreased MRP1 levels
under conditions of folate deficiency were presumably crucial
adaptations aimed at augmenting cellular folate retention.
These findings are in agreement with several in vivo and in
vitro studies that explored the effect of folate deficiency on
cellular FPGS activity and the expression of various MRPs. (a)
Mice fed a low folate diet displayed a 50% increase in liver
FPGS activity (41). (b) In a recent study (42) we characterized
Chinese hamster ovary cells that were subjected to gradually
increasing concentrations of the lipid-soluble antifolate, py-
rimethamine (40), thereby resulting in a gradually increasing
folate deprivation (39). Consequently, these cells displayed a
3–4-fold increase in FPGS activity (39) along with a complete
loss of MRP1 expression (42). Furthermore, these cells were
also devoid of BCRP and MRP2 through MRP4 even before
pyrimethamine selection took place. Hence, in the absence of
an ABC transporter that would mediate folate efflux activity,
these cells could grow on extremely low concentrations of fo-
lates (e.g. pM concentrations of leucovorin). (c) Recently we have
shown (43) that human leukemia cells adapted to grow under
extremely low concentrations of leucovorin had a 95% loss of
MRP1 expression and folate efflux function along with a 100-
fold overexpression of the RFC, the primary folate influx trans-
porter. In conclusion, disruption of folate exporter function via
loss of BCRP and/or MRP1 expressions along with a concomi-
tant increase in FPGS activity are apparently essential adap-
tations to conditions of folate deficiency, thereby resulting in an
increased capacity to accumulate and retain cellular folates.
We consistently find here that MCF-7/MR-LF and MCF-7/LF
cells accumulated significantly higher levels of [3H]folic acid
than their parental counterparts.
As mentioned above, we have shown recently (43) that grad-
ual deprivation of leucovorin (5-formyltetrahydrofolate) from
the growth medium of human CCRF-CEM leukemia cells re-
sulted in a 95% loss of MRP1 expression. Consistently, replen-
ishment of the latter cells with 5 nM leucovorin resulted in a
FIG. 5. Cellular growth inhibition with MR. Parental MCF-7 and
MCF-7-LF (A) as well as parental MCF-7, MCF-7/MR-HF, and MCF-7/
MR-LF cells (B) growing in monolayers in 24-well plates were exposed
to various concentrations of MR in the absence or presence of 0.3 M
Ko143, a potent BCRP inhibitor. Following 72 h of incubation at 37 °C,
cells were detached by trypsinization, and the number of viable cells
was determined using trypan blue exclusion. Results depicted are the
means  S.D. of three independent experiments.
FIG. 6. Cellular growth inhibition with MTX. Cells were seeded
in 24-well plates and allowed to attach for 24 h at 37 °C. Attached cells
were then exposed continuously (A) or pulsed for 4 h at 37 °C with
various concentrations of MTX (B and C). Following 4 h of exposure to
MTX, the drug-containing medium was removed, and three successive
washes each of 10 min in drug-free medium were performed at 37 °C.
Drug-free growth medium was added (2 ml/well), and cultures were
incubated for 4 days at 37 °C. Cells were then detached by trypsiniza-
tion, and the number of viable cells was determined using trypan blue
exclusion.
ABCG2 and Folate Homeostasis25532
 at Vrije Universiteit, Medical Library, on December 21, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
complete restoration of MRP1 expression. In a recent paper
(44) we reported that under folate-free conditions, MRP1- and
MRP3-overexpressing cell lines were impaired in cellular
growth upon a short exposure (4 h) to folic acid or leucovorin,
when compared with their parental cells. Furthermore, the
folic acid growth stimulation capacity in these cells was dra-
matically decreased during the pulse exposure to folic acid,
when metabolism into rapidly polyglutamatable and hence re-
tainable dihydrofolate and tetrahydrofolate was blocked by
trimetrexate, a dihydrofolate reductase inhibitor. In another
study (42), as mentioned above, we subjected Chinese hamster
ovary cells to gradually increasing concentrations of the lipid-
soluble antifolate pyrimethamine (40). This gradually increas-
ing folate deprivation (39) resulted in a complete loss of MRP1
expression (42). Taken together, these findings suggest that
down- and up-regulation of the ubiquitously expressed MRP1
can readily influence cellular folate homeostasis, particularly
when cellular folate retention by polyglutamylation is
attenuated.
Based on the unique substrate specificity of BCRP that is
capable of exporting mono-, di-, and triglutamate conjugates of
folates, one could predict that expression of substantial BCRP
levels would not be compatible with folate deficiency condi-
tions. Indeed, although MCF-7 cells expressed 5-fold more
MRP1 than BCRP levels, the LF-adapted subline MCF-7/LF
almost completely lost BCRP expression with no change in
MRP1 levels. In contrast, following folate deprivation, MCF-
7/MR cells with 55-fold BCRP overexpression, relative to pa-
rental MCF-7 cells, had a near complete loss of BCRP and
MRP1 expression. Hence, elimination of the low expression
levels of BCRP in MCF-7/LF cells was apparently sufficient to
meet their folate growth requirement. In contrast, the dramatic
down-regulation of the initially very high levels of BCRP in
MCF-7/MR cells was crucial but apparently not sufficient as
MRP1 expression was down-regulated to barely detectable lev-
els. It is possible that this repression in MRP1 expression was
achieved in the following manner: when BCRP was decreased
to levels that were comparable with those of MRP1, the latter
became significant in its contribution to folate efflux, thereby
promoting its down-regulation as well. Support for this hypoth-
esis could derive from the fact that replenishment of MCF-7/
MR-LF cells with 2.3 M folic acid for 1 month resulted in
restoration of MRP1 expression to levels that exceeded those of
parental MCF-7 cells (data not shown). In contrast, no resto-
ration of BCRP expression was observed in these cells. Clearly,
resumption of substantial levels of BCRP, an exporter that
extrudes the precious triglutamate conjugates of folates, was
not consistent with the retention of sufficient cellular folate
pools to support cell growth.
Both MRP1 and BCRP are capable of ATP-driven efflux of
folate monoglutamates. However, whereas MRP1 is ubiqui-
tously expressed at substantial levels in various tissues, BCRP
is relatively poorly expressed, and its pattern of tissue expres-
sion is apparently restricted to only a few tissues including
placenta, intestine, colon, and the bile canaliculus. Most inter-
esting, all these tissues were reported to express high levels of
FPGS mRNA (45) and displayed a relatively high activity of
FPGS. Hence, based on the unique folate polyglutamate ex-
porter function of BCRP as well as on the ubiquitous expression
of MRP1, it is tempting to speculate that expression of substan-
tial levels of BCRP should be accompanied by adequate levels
of FPGS activity in order to ensure sufficient intracellular
retention of long chain (3 glutamate residues) folate
polyglutamates.
The present finding of the loss of BCRP expression under
conditions of folate deficiency may have potentially important
implications for anticancer chemotherapy including MR-con-
taining chemotherapy. First, MR is being used in the treatment
of metastatic breast cancer and non-lymphocytic leukemia in-
cluding acute granulocytic leukemia. Breast cancer patients
are initially treated with a chemotherapeutic regimen that
contains either MTX or doxorubicin. However, one mechanism
of MTX resistance in breast cancer cells may be antifolate drug
transport (47, 48). This may be because of the loss of gene
expression and function of RFC, the primary transporter for
folates and MTX. Consequently, such folate transport-deficient
and MTX-resistant cells may suffer from a markedly dimin-
ished intracellular folate pool (49). Cell survival on such a
shrunken cellular folate pool may be associated with a signifi-
FIG. 7. [3H]Folic acid accumulation in parental and LF-
adapted cell lines. Monolayer cells were washed with folate-free me-
dium and then incubated for 4 (A) and 24 h (B) at 37 °C in HBS
containing 1 M [3H]folic acid as described under “Experimental Proce-
dures.” Transport was stopped by the addition of 10 ml of ice-cold HBS.
Cells were then detached by trypsinization, washed with ice-cold HBS,
and the final cell pellet was lysed in 0.2 ml of water, and the radioac-
tivity released was determined using a liquid scintillation spectrome-
ter. The asterisks denote statistically significant changes in MCF-7/LF
versus parental MCF-7 cells, as well as MCF-7/MR-LF versus its MCF-
7/MR-HF parental counterpart.
FIG. 8. Histogram of FPGS activity in parental cells and their
LF-adapted cell lines. The catalytic activity of FPGS in the cytosolic
fraction isolated from the various cell lines was determined as described
under “Experimental Procedures.” Results presented are the means 
S.D. of three independent experiments. The asterisks denote statisti-
cally significant changes in the LF-adapted sublines when compared
with their parental cell lines.
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cant down-regulation of MRP1 and/or BCRP (42, 43). Hence,
such MTX-resistant breast cancer cells may be most vulnerable
to the cytotoxic action of various chemotherapeutic agents in-
cluding anthracyclines and MR. This consideration may possi-
bly have therapeutic value in overcoming drug resistance of
certain tumors that have down-regulated the expression of
BCRP under folate deficiency conditions. Second, we have
shown here that folate deprivation results in the loss of MRP1
and BCRP expression. As such, one potential strategy to over-
come anticancer drug resistance that is based on MRP1 and/or
BCRP overexpression could be a transient exposure of the
tumors to a folate-deficient diet. This could lead to a marked
down-regulation of MRP1 and/or BCRP, thereby resulting in
increased sensitivity of the tumors to various chemotherapeu-
tic agents.
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